Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein mago nashi homolog B (MAGOHB) is a core member of the exon junction complex (EJC), a multi-protein assembly that binds to mRNA near exon-exon junctions following splicing[1][2][4]. MAGOHB, together with its paralog MAGOH, partners with other EJC core proteins (eIF4A3, Y14) to regulate post-transcriptional processes, including mRNA export, localization, translation, and notably nonsense-mediated decay (NMD) to eliminate faulty mRNAs[1][2][4]. High MAGOHB expression is seen in malignant tumors such as glioblastoma and melanoma, where it is implicated in enhanced cell proliferation and survival. Knockdown studies indicate that depletion of MAGOHB (alone or combined with MAGOH) disrupts splicing precision, impairs NMD, and promotes apoptosis, suggesting that the EJC’s RNA surveillance role is critical for rapidly dividing cells[1][4]. MAGOHB is not typically classified as a classic drug target (receptor, enzyme, ion channel), but its fundamental roles in RNA biology and cancer make it a protein of interest for basic research and potential future interventions[1][2][4].
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein mago nashi homolog B (MAGOHB).